Lidocaine protects against renal and hepatic dysfunction in septic rats via downregulation of Toll‑like receptor 4

Liu,Jinbo; Zhang,Haohua; Qi,Zongcai; Zheng,Xiuying

doi:10.3892/mmr.2013.1799

Lidocaine protects against renal and hepatic dysfunction in septic rats via downregulation of Toll‑like receptor 4

Authors:
- Jinbo Liu
- Haohua Zhang
- Zongcai Qi
- Xiuying Zheng
View Affiliations

Affiliations: Department of Anesthesiology, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China, Department of Anesthesiology, Brain Branch of Weifang People's Hospital, Weifang, Shandong 261041, P.R. China
Published online on: November 14, 2013 https://doi.org/10.3892/mmr.2013.1799
Pages: 118-124

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was designed to determine the renoprotective and hepatoprotective effect of lidocaine in septic rats through the Toll‑like receptor 4 (TLR4) signaling pathway. Adult male Sprague‑Dawley rats were randomly divided into the following three groups: control, sepsis model and 10% lidocaine. A model of sepsis was established by injection of lipopolysaccharide (LPS; 5 mg/kg) into the intraperitoneal cavity of rats. The same volume of saline was injected intraperitoneally into rats of the control group instead of LPS. Light microscopy was used to observe structural changes of the hepatic and nephridial tissues. qPCR was used to measure TLR4 mRNA expression levels and the protein expression was detected by flow cytometry. Western blotting was used to measure myocardial nuclear factor κB (NF‑κB) protein levels and ELISA was used to measure the levels of interleukin‑6 (IL‑6) in hepatic and nephridial tissues. The results demonstrated that 10% lidocaine treatment markedly decreased hepatic and nephridial injury in septic rats and inhibited the expression levels of TLR4, NF‑κB and IL‑6, which were upregulated in the sepsis model. In addition, the results indicated that lidocaine protects against renal and hepatic dysfunction in septic rats, which may be mediated by the downregulation of TLR4 and associated signaling molecules and inhibition of the inflammatory response.

View Figures

View References

1	Wang H and Ma S: The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med. 26:711–715. 2008. View Article : Google Scholar : PubMed/NCBI
2	Dewar DC and Balogh ZJ: The epidemiology of multiple-organ failure: a definition controversy. Acta Anaesthesiol Scand. 55:248–249. 2011. View Article : Google Scholar : PubMed/NCBI
3	Dinarello CA: Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 112:S321–S329. 1997. View Article : Google Scholar : PubMed/NCBI
4	Cohen J: The immunopathogenesis of sepsis. Nature. 420:885–891. 2002. View Article : Google Scholar : PubMed/NCBI
5	Brun-Buisson C: The epidemiology of the systemic inflammatory response. Intensive Care Med. 26(Suppl 1): S64–S74. 2000. View Article : Google Scholar
6	Angus DC and Wax RS: Epidemiology of sepsis: an update. Crit Care Med. 29:S109–S116. 2001. View Article : Google Scholar : PubMed/NCBI
7	Hollmann MW and Durieux ME: Local anesthetics and the inflammatory response: a new therapeutic indication? Anesthesiology. 93:858–875. 2000. View Article : Google Scholar : PubMed/NCBI
8	Strohm C, Barancik T, Bruhl ML, Kilian SA and Schaper W: Inhibition of the ER-kinase cascade by PD98059 and UO126 counteracts ischemic preconditioning in pig myocardium. J Cardiovasc Pharmacol. 36:218–229. 2000. View Article : Google Scholar : PubMed/NCBI
9	Das KC and Misra HP: Prevention of reperfusion lung injury by lidocaine in isolated rat lung ventilated with higher oxygen levels. J Postgrad Med. 49:17–20. 2003. View Article : Google Scholar : PubMed/NCBI
10	Schmid RA, Yamashita M, ando K, Tanaka Y, Cooper JD and Patterson GA: Lidocaine reduces reperfusion injury and neutrophil migration in canine lung allografts. Ann Thorac Surg. 61:949–955. 1996. View Article : Google Scholar : PubMed/NCBI
11	Tomori H, Shiraishi M, Koga H, et al: Protective effects of lidocaine in hepatic ischemia/reperfusion injury in vitro. Transplant Proc. 30:3740–3742. 1998. View Article : Google Scholar : PubMed/NCBI
12	Fuentes JM, Talamini MA, Fulton WB, Hanly EJ, Aurora AR and De Maio A: General anesthesia delays the inflammatory response and increases survival for mice with endotoxic shock. Clin Vaccine Immunol. 13:281–288. 2006. View Article : Google Scholar : PubMed/NCBI
13	Gallos G, Jones DR, Nasr SH, Emala CW and Lee HT: Local anesthetics reduce mortality and protect against renal and hepatic dysfunction in murine septic peritonitis. Anesthesiology. 101:902–911. 2004. View Article : Google Scholar : PubMed/NCBI
14	Kawai T and Akira S: TLR signaling. Cell Death Differ. 13:816–825. 2006. View Article : Google Scholar
15	Akira S: TLR signaling. Curr Top Microbiol Immunol. 311:1–16. 2006.
16	Compton T, Kurt-Jones EA, Boehme KW, et al: Human cytomegalovirus activates inflammatory cytokine responses via CD14 and toll-like receptor 2. J Virol. 77:4588–4596. 2003. View Article : Google Scholar : PubMed/NCBI
17	Tanimura N, Saitoh S, Matsumoto F, Akashi-Takamura S and Miyake K: Roles for LPS-dependent interaction and relocation of TLR4 and TRAM in TRIF-signaling. Biochem Biophys Res Commun. 368:94–99. 2008. View Article : Google Scholar : PubMed/NCBI
18	Kawai T and Akira S: The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 11:373–384. 2010. View Article : Google Scholar : PubMed/NCBI
19	Rittirsch D, Flierl MA and Ward PA: Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 8:776–787. 2008. View Article : Google Scholar : PubMed/NCBI
20	Akira S and Hemmi H: Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett. 85:85–95. 2003. View Article : Google Scholar : PubMed/NCBI
21	Muzio M, Bosisio D, Polentarutti N, et al: Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol. 164:5998–6004. 2000. View Article : Google Scholar : PubMed/NCBI
22	O’Neill LAJ and Bowie AG: The family of five: TIR- domain-containing adaptors in toll-like receptor signalling. Nat Rev Immunol. 7:353–364. 2007.
23	Zhang FX, Kirschning CJ, Mancinelli R, et al: Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem. 274:7611–7614. 1999. View Article : Google Scholar
24	Cario E, Rosenberg IM, Brandwein SL, Beck PL, Reinecker HC and Podolsky DK: Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing toll-like receptors. J Immunol. 164:966–972. 2000. View Article : Google Scholar : PubMed/NCBI
25	Faure E, Equils O, Sieling PA, et al: Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem. 275:11058–11063. 2000. View Article : Google Scholar
26	Underhill DM, Ozinsky A, Smith KD and Aderem A: Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci USA. 96:14459–14463. 1999. View Article : Google Scholar : PubMed/NCBI
27	Ozinsky A, Underhill DM, Fontenot JD, et al: The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA. 97:13766–13771. 2000. View Article : Google Scholar : PubMed/NCBI
28	Poltorak A, He X, Smirnova I, et al: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 282:2085–2088. 1998. View Article : Google Scholar
29	Ahn KS, Sethi G and Aggarwal BB: Nuclear factor-kappa B: from clone to clinic. Curr Mol Med. 7:619–637. 2007. View Article : Google Scholar : PubMed/NCBI
30	Lu YC, Yeh WC and Ohashi PS: LPS/TLR4 signal transduction pathway. Cytokine. 42:145–151. 2008. View Article : Google Scholar
31	Hoffmann A, Natoli G and Ghosh G: Transcriptional regulation via the NF-kappaB signaling module. Oncogene. 25:6706–6716. 2006. View Article : Google Scholar : PubMed/NCBI
32	Hoffmann A, Levchenko A, Scott ML and Baltimore D: The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science. 298:1241–1245. 2002. View Article : Google Scholar
33	Couture LA, Piao W, Ru LW, Vogel SN and Toshchakov VY: Targeting toll-like receptor (TLR) signaling by toll/interleukin-1 receptor (TIR) domain-containing adapter protein/MyD88 adapter-like (TIRAP/Mal)-derived decoy peptides. J Biol Chem. 287:24641–24648. 2012. View Article : Google Scholar : PubMed/NCBI
34	Fitzgerald KA, Palsson-McDermott EM, Bowie AG, et al: Mal (MyD88-adapter-like) is required for toll-like receptor-4 signal transduction. Nature. 413:78–83. 2001. View Article : Google Scholar : PubMed/NCBI
35	Gray P, Dunne A, Brikos C, Jefferies CA, Doyle SL and O’Neill LA: MyD88 adapter-like (Mal) is phosphorylated by Bruton’s tyrosine kinase during TLR2 and TLR4 signal transduction. J Biol Chem. 281:10489–10495. 2006.PubMed/NCBI
36	Verstak B, Nagpal K, Bottomley SP, Golenbock DT, Hertzog PJ and Mansell A: MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-kappaB proinflammatory responses. J Biol Chem. 284:24192–24203. 2009. View Article : Google Scholar : PubMed/NCBI
37	Brown KL, Cosseau C, Gardy JL and Hancock RE: Complexities of targeting innate immunity to treat infection. Trends Immunol. 28:260–266. 2007. View Article : Google Scholar : PubMed/NCBI
38	Hoshino K, Takeuchi O, Kawai T, et al: Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 162:3749–3752. 1999.PubMed/NCBI
39	Arbour NC, Lorenz E, Schutte BC, et al: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 25:187–191. 2000. View Article : Google Scholar : PubMed/NCBI
40	Johnson GB, Brunn GJ and Platt JL: Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J Immunol. 172:20–24. 2004. View Article : Google Scholar : PubMed/NCBI
41	Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J and Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med. 29:1303–1310. 2001. View Article : Google Scholar : PubMed/NCBI
42	Li CY, Tsai CS, Hsu PC, Chueh SH, Wong CS and Ho ST: Lidocaine attenuates monocyte chemoattractant protein-1 production and chemotaxis in human monocytes: possible mechanisms for its effect on inflammation. Anesth Analg. 97:1312–1316. 2003.PubMed/NCBI
43	Takao Y, Mikawa K, Nishina K, Maekawa N and Obara H: Lidocaine attenuates hyperoxic lung injury in rabbits. Acta Anaesthesiol Scand. 40:318–325. 1996. View Article : Google Scholar : PubMed/NCBI
44	Sinclair R, Eriksson AS, Gretzer C, Cassuto J and Thomsen P: Inhibitory effects of amide local anaesthetics on stimulus-induced human leukocyte metabolic activation, LTB4 release and IL-1 secretion in vitro. Acta Anaesthesiol Scand. 37:159–165. 1993. View Article : Google Scholar